Print the page
Identifying new indications of clinically approved drugs for treating the cancer specific to a particular patient
Liver, colon, lung and bladder cancers are common causes of deaths worldwide. Surgical resection and conventional chemotherapy and radiotherapy are likely to fail because of tumor recurrence and resistance. Hence, finding appropriate medications on a personal basis is now being intensively researched. We have recently developed a series of computer software to realize automatic identification of novel indications of approved drugs for the treatment of patient-specific cancer subtype via targeting the pharmacological oncoprotein mutants of a particular patient. In real-world applications, by utilizing the in-house in silico tools, we managed to reposition several clinically approved drugs as anticancer agents and filed patent applications for five of them.
Uniqueness and Competitive Advantages:
- Repurposing existing drugs greatly reduces the cycle and cost of the research and development of new drugs
- The development risk is reduced since existing drugs are approved and have been shown to be safe in late-stage trials
- In a general sense, the applicability domain of our toolset could be expanded to treating any kind of diseases